Skip to main content

LLS News Network

LLS News Network

LLS Applauds House Passage of Critical Health Reforms

Rye Brook, N.Y., Nov. 19, 2021 — The Leukemia & Lymphoma Society applauds passage of critical patient-friendly reforms by the U.S. House of Representatives. The provisions, components of the Build Back Better Act, represent a key step towards ensuring millions of people — including cancer patients and survivors — have access to quality, affordable healthcare. LLS urges the U.S. Senate to pass these policies without delay.

Read More

FDA APPROVES THE FIRST INTERFERON FOR ADULTS WITH POLYCYTHEMIA VERA

Rye Brook, N.Y., November 16, 2021 – The U.S. Food and Drug Administration (FDA) last week announced approval of ropeginterferon alfa-2b-njft (ropeg, BESREMi®) for the treatment of polycythemia vera (PV). This is the first medication approved for PV that patients can take regardless of their treatment history, meaning it can be used to treat this rare form of cancer early, which may help reduce the risk of progression over time.

Read More

FDA Approves New Treatment Option for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Rye Brook, N.Y., November 11, 2021 – The U.S. Read More

Media Requests

Please send all media-related inquiries and interview requests to mediarelations@lls.org. An LLS representative will respond as soon as possible.